首页> 外文期刊>Journal of Hepato-Biliary-Pancreatic Sciences >Medical treatments: in association or alone, their role and their future perspectives Novel molecular-targeted therapy for hepatocellular carcinoma
【24h】

Medical treatments: in association or alone, their role and their future perspectives Novel molecular-targeted therapy for hepatocellular carcinoma

机译:药物治疗:联合使用或单独使用,其作用和未来展望新型分子靶向治疗肝细胞癌

获取原文
获取原文并翻译 | 示例
       

摘要

Accumulated understanding of the molecular networks in the state of oncogene addiction, i.e., the “Achilles’ heel of cancer,” has led to the development of novel targeted therapies. Using genome-wide gene expression and network analysis, we have identified “Aurora kinase B” as a unique molecule to predict the lethal recurrence of hepatocellular carcinoma (HCC) even after curative hepatectomy. Comparative genomic hybridization (CGH)-array analysis revealed the genomic instability was closely related to Aurora kinase B expression in HCC. Then, we analyzed the in vitro and in vivo effects of a selective inhibitor of Aurora kinase B on human HCC cells. Treatment with Aurora B inhibitor in vitro resulted in polyploidy and apoptotic cell death. The growth of orthotopic liver tumors was significantly suppressed by the Aurora B inhibitor. Our preclinical studies indicate that Aurora kinase B is a promising molecular target “Achilles’ heel” for the treatment of aggressive HCC.
机译:对致癌基因成瘾状态下的分子网络的累积理解,即“癌症的致命弱点”,导致了新型靶向疗法的发展。使用全基因组基因表达和网络分析,我们已经确定“极光激酶B”是预测肝细胞癌(HCC)致死性复发的独特分子,即使在治愈性肝切除术后也是如此。比较基因组杂交(CGH)-阵列分析显示,基因组不稳定性与肝癌中Aurora激酶B的表达密切相关。然后,我们分析了Aurora激酶B选择性抑制剂对人HCC细胞的体外和体内作用。体外用Aurora B抑制剂治疗会导致多倍性和凋亡细胞死亡。 Aurora B抑制剂可显着抑制原位肝肿瘤的生长。我们的临床前研究表明,Aurora激酶B是用于治疗侵袭性HCC的有希望的分子靶点“致命弱点”。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号